{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T07:45:22Z","timestamp":1781768722808,"version":"3.54.5"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T00:00:00Z","timestamp":1430352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2015,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Left ventricular assist devices (<jats:styled-content style=\"fixed-case\">LVAD<\/jats:styled-content>s) as a bridge to transplant (<jats:styled-content style=\"fixed-case\">BTT<\/jats:styled-content>) have been known to cause allosensitization, as measured by panel\u2010reactive antibody (<jats:styled-content style=\"fixed-case\">PRA<\/jats:styled-content>) levels. The goal of this study was to measure the impact of this allosensitization on outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Panel\u2010reactive antibodies were analyzed in <jats:styled-content style=\"fixed-case\">BTT<\/jats:styled-content> patients, with sensitization defined as peak <jats:styled-content style=\"fixed-case\">PRA<\/jats:styled-content>s\u00a0\u2265\u00a010%. Baseline characteristics and outcomes in the two patient groups were evaluated using descriptive statistics, <jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>aplan\u2013<jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>eier, and regression analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Thirty\u2010eight patients were included in the study (17 sensitized vs. 21 non\u2010sensitized). There were more women in the sensitized group (47% vs. 10%, p<jats:italic>\u00a0<\/jats:italic>=\u00a00.023). There was no difference in mean times to high\u2010grade acute cellular rejection (<jats:styled-content style=\"fixed-case\">ACR<\/jats:styled-content>; 18.3\u00a0months in sensitized vs. 36.9\u00a0months in non\u2010sensitized). Five patients in the sensitized groups developed antibody\u2010mediated rejection (<jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content>) vs. 0 in the non\u2010sensitized, and all five patients died (<jats:styled-content style=\"fixed-case\">K<\/jats:styled-content>aplan\u2013<jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>eier log\u2010rank p\u00a0=\u00a00.024). There was also a significant difference in the incidence of infection at the one\u2010 to six\u2010month stage (52.9% vs. 19.0%, p\u00a0=\u00a00.03).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Sensitization appears to have a negative effect on mortality. This mortality appears to be concentrated in patients with <jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content>, and we postulate that the development of <jats:styled-content style=\"fixed-case\">AMR<\/jats:styled-content> in a sensitized patient may be a predictor of mortality.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ctr.12540","type":"journal-article","created":{"date-parts":[[2015,3,13]],"date-time":"2015-03-13T15:00:57Z","timestamp":1426258857000},"page":"499-505","source":"Crossref","is-referenced-by-count":31,"title":["Clinical outcomes in sensitized heart transplant patients bridged with ventricular assist devices"],"prefix":"10.1111","volume":"29","author":[{"given":"Sumanth","family":"Kidambi","sequence":"first","affiliation":[{"name":"Division of Advanced Heart Failure and Clinical Transplantation Advocate Christ Medical Center Oak Lawn IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burhan","family":"Mohamedali","sequence":"additional","affiliation":[{"name":"Rush University Chicago IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6500-0437","authenticated-orcid":false,"given":"Geetha","family":"Bhat","sequence":"additional","affiliation":[{"name":"Division of Advanced Heart Failure and Clinical Transplantation Advocate Christ Medical Center Oak Lawn IL USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,4,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-012-9298-y"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(03)00480-6"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2009.04.031"},{"key":"e_1_2_7_5_1","first-page":"II294","article-title":"Pretransplant panel reactive antibody screens. Are they truly a marker for poor outcome after cardiac transplantation?","volume":"94","author":"Kobashigawa JA","year":"1996","journal-title":"Circulation"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199402270-00026"},{"key":"e_1_2_7_7_1","first-page":"921","article-title":"Influence of panel reactive antibody and lymphocytotoxic crossmatch on survival after heart transplantation","volume":"10","author":"Lavee J","year":"1991","journal-title":"J Heart Lung Transplant"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0b013e31826d6070"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182985371"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0003-4975(97)00807-2"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2007.04.023"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2009.06.015"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2010.05.034"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02987.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(99)00018-2"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2006.11.062"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(02)00448-5"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1053\/pcad.2000.7191"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.98.8.786"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(00)00459-9"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2007.11.049"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2011.05.119"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-2498(01)00232-7"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2003.12.008"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fctr.12540","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ctr.12540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T12:15:16Z","timestamp":1696248916000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ctr.12540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,30]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.1111\/ctr.12540"],"URL":"https:\/\/doi.org\/10.1111\/ctr.12540","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,30]]}}}